Xiaflex 0.9 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FQHU5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,362
Award facts
- Contract value 100% obligated
- $4,361.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $4,361.95 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xiaflex 0.9 mg vials. The delivery order, awarded on January 6, 2026, with an ultimate completion date of January 28, 2026, operates under a firm fixed-price structure with no set-aside designation. This award represents a routine procurement action issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion federal acquisition strategy designed to streamline pharmaceutical supply chain operations across Department of Defense healthcare facilities.
DMS Pharmaceutical Group serves as a critical regional prime vendor contractor under the PPV-G GEN V program, which was established to provide comprehensive pharmaceutical sourcing including branded and generic prescription medications, biologics, and medical consumables to military medical facilities worldwide. The company's single-award indefinite delivery contract under this program, designated SPE2DR and valued at up to $499.999 billion, extends through December 31, 2036, with a 30-month base period and three optional 30-month extension periods. This delivery order for Xiaflex vials exemplifies the type of specialized pharmaceutical products DMS Pharmaceutical Group routinely supplies to support recurring Department of Defense medical supply requirements.
Quick answers
Who was awarded contract SPE2DR26FQHU5?
SPE2DR26FQHU5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FQHU5 worth?
The government has obligated $4,362 on SPE2DR26FQHU5.
Is contract SPE2DR26FQHU5 an order under another contract?
Yes. SPE2DR26FQHU5 is a delivery order under SPE2DR25D9759, an indefinite delivery contract.
Was contract SPE2DR26FQHU5 competed?
The extent of competition for SPE2DR26FQHU5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award